Skip to main content
Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. Rosenberg, J. E., Flaig, T. W., Friedlander, T. W., Milowsky, M., Srinivas, S., Petrylak, D., Merchan, J. R., Bilen, M., Carret, A., Yuan, N., Sasse, C., Hoimes, C. J. AMER SOC CLINICAL ONCOLOGY. 2020

View details for Web of Science ID 000560368302300